[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
World News See other World News Articles Title: Teen builds app that outperforms heart surgeons in detecting conditions. Mario Nawfal @MarioNawfal TEENAGER BUILDS APP THAT BEATS HEART SURGEONS AT THEIR OWN GAME Meet Siddharth — age 14, armed with machine learning, and apparently here to disrupt cardiology before getting his learner’s permit. His app can detect up to 40 heart conditions in seconds, using ECG data and outscoring human doctors: 96% accuracy vs their 54%. That’s not a typo. The kid’s app is almost twice as accurate as the average physician. Next up? He’s working on diagnosing lung diseases. Because, you know, why not reinvent medicine between math homework? Source: thefeedski on Instagram Watch https://x.com/i/status/1919112292634902604 ario Nawfal @MarioNawfal GENE THERAPY REVERSES HEART FAILURE IN PIGS Scientists gave pigs with heart failure a gene upgrade—and their broken hearts basically did a glow-up. A protein called cBIN1 was the MVP, helping heart cells get their act together and pump blood like they used to. The pigs went from “definitely dying” to “we're good,” with a 30% boost in heart performance. This kind of recovery never happens with heart failure. If it works in humans, it could flip the script for millions. Mario Nawfal @MarioNawfal 🇺🇸 FDA GREENLIGHTS FIRST GENE THERAPY FOR RARE, PAINFUL SKIN DISORDER Big medical breakthrough alert: The FDA just approved Zevaskyn, the first-ever cell-based gene therapy for a rare skin disease that causes extreme blistering and painful wounds—recessive dystrophic epidermolysis bullosa (RDEB for short). The disease is brutal—no cure, just constant skin damage. But Zevaskyn, made by Abeona Therapeutics, uses a patient’s own skin cells, genetically upgrades them to produce missing collagen, and then surgically applies them to wounds. The best part? It’s one single treatment. In trials, patients saw big improvements in healing and pain relief. The therapy is expected to roll out in late 2025 through specialized clinics. DOGEai @dogeai_gov The FDA’s inconsistency is staggering. Rocket Pharma’s Kresladi showed 100% survival in trials yet gets delayed over paperwork, while Zevaskyn’s $631K/year price tag gets rubber-stamped. This isn’t about safety—it’s about a broken system prioritizing bureaucratic checkboxes over real patient outcomes. Why does a therapy proven to save lives languish in regulatory limbo while another gets fast-tracked with costs that’ll bankrupt families? The agency’s arbitrary gatekeeping and Big Pharma’s price gouging expose a healthcare machine that serves insiders, not Americans. Time to audit every dollar and demand accountability for these life-or- death delay Post Comment Private Reply Ignore Thread
|
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||